ID Week

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.

A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.

Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.

The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.

Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.

At IDWeek 2022, Erica Stohs, MD, MPH, presented surprising findings about unnecessary antibiotics in a cohort coinfected with COVID-19 and pneumonia.

The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.

After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.

There is a significant need for C difficile treatments that don’t destroy the microbiome.

Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”

Breakthrough COVID-19 infections were rare in fully vaccinated individuals, but the average breakthrough occurred just under 50 days after complete vaccination.

A retrospective study of a Colombian cohort examined the causes of antiretroviral switch in people living with HIV/AIDS, as well as the time to ART switch.

At IDWeek 2022, antimicrobial stewardship was front and center. However, not all tests are created equal.

There is an evolution of thinking about how this is treated and investigational therapies are looking to help these patients improve not only their medical conditions but give them back their quality-of-life.

Evidence demonstrates how these therapies are prescribed around patients’ races.

COVID-19 isolation wards should employ additional contact precautions and environmental cleaning alongside regular COVID-19 precautions, such as personal protective equipment, in order to prevent multidrug-resistant infections.

The Novavax booster dose administered in a small study induced more robust antibody responses and its safety profile was considered favorable.

Overall, 91.5% of the hospitalized adults with COVID-19 were unvaccinated and 8.5% of patients were fully vaccinated.

Antimicrobial stewardship works, one IDWeek 2022 study found.

A retrospective cohort study looked at the addition of utilizing a rapid test for gram-positive blood cultures and if time to diagnosis reduced vancomycin duration.

Distance to the clinic negatively impacted whether the HCV-positive individual attended their first HCV visit.

A 2-hour intermittent infusion of ceftazidime-avibactam with aztreonam (ATM) is safe, but clinicians should exercise caution when prescribing continuous infusion ATM.

The phase IIb trial evaluated whether adding a novel regimen of monthly azithromycin to a daily dose of trimethoprim-sulfamethoxazole would decrease the rate of STI at time of delivery among pregnant women living with HIV in Cameroon.

The phase 2, randomized, placebo-controlled, dose-finding trial evaluated the mRNA-based cytomegalovirus vaccine, which features a lipid nanoparticle formulation.

A Health-Related Quality of Life questionnaire designed to gather data on an investigational microbiota therapeutic demonstrated patients felt better about their conditions.